Tertiary Lymphoid Organs in Neurodegeneration

Tertiary Lymphoid Organs in Neurodegeneration

Path: `/mechanisms/tertiary-lymphoid-organs-neurodegeneration`

Category: Mechanism

Overview

Tertiary lymphoid organs (TLOs), also known as ectopic lymphoid structures, are organized lymphoid aggregates that form in non-lymphoid tissues during chronic inflammation. In the central nervous system (CNS), TLOs have been identified in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. These structures serve as local hubs for immune cell activation, antigen presentation, and autoantibody production, playing a complex role in disease progression and representing potential therapeutic targets.[@tertiary2018]

Structure and Composition

Organizational Features

TLOs share structural similarities with secondary lymphoid organs:

• Follicular architecture: B-cell follicles with germinal centers
• T-cell zones: Parafollicular T-cell rich regions
• Dendritic cell networks: Specialized antigen-presenting cells
• High endothelial venules (HEVs): Venules specialized for lymphocyte recruitment
• Fibroblastic reticular cells (FRCs): Stromal framework supporting organization[@structure2019]

Cellular Composition

TLOs contain diverse immune cell populations:

...

Tertiary Lymphoid Organs in Neurodegeneration

Path: `/mechanisms/tertiary-lymphoid-organs-neurodegeneration`

Category: Mechanism

Overview

Tertiary lymphoid organs (TLOs), also known as ectopic lymphoid structures, are organized lymphoid aggregates that form in non-lymphoid tissues during chronic inflammation. In the central nervous system (CNS), TLOs have been identified in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. These structures serve as local hubs for immune cell activation, antigen presentation, and autoantibody production, playing a complex role in disease progression and representing potential therapeutic targets.[@tertiary2018]

Structure and Composition

Organizational Features

TLOs share structural similarities with secondary lymphoid organs:

• Follicular architecture: B-cell follicles with germinal centers
• T-cell zones: Parafollicular T-cell rich regions
• Dendritic cell networks: Specialized antigen-presenting cells
• High endothelial venules (HEVs): Venules specialized for lymphocyte recruitment
• Fibroblastic reticular cells (FRCs): Stromal framework supporting organization[@structure2019]

Cellular Composition

TLOs contain diverse immune cell populations:

| Cell Type | Function |
|-----------|----------|
| B cells | Antigen-specific antibody production |
| Plasma cells | Local antibody secretion |
| CD4+ T helper cells | Cytokine production, B cell help |
| CD8+ T cytotoxic cells | Direct cell killing |
| Follicular dendritic cells | B cell selection in germinal centers |
| Dendritic cells | Antigen presentation |
| Macrophages | Phagocytosis, cytokine secretion |

Formation Mechanisms

Cytokine Networks

TLO formation requires coordinated cytokine signaling:

LTα1β2/LTβR signaling: Lymphotoxin pathway drives stromal cell organization

IL-17/IL-22: Th17 cytokines promote lymphoid neogenesis

CXCL13/CXCR5: B cell follicle formation

CCL19/CCL21/CCR7: T cell zone organization

BAFF/APRIL: B cell survival and maturation[@cytokine2020]

Cellular Requirements

Key cellular players in TLO formation:

• Innate lymphoid cells (ILC3): Produce IL-22 and LTα
• Th17 cells: Provide IL-17 and IL-22
• B1 B cells: Initial B cell population
• Mesenchymal stromal cells: Differentiate into FRCs

Tissue Context

TLOs form preferentially in regions of:

• Chronic inflammation
• Tissue damage and remodeling
• Proximity to vasculature
• Areas with persistent antigen presence

TLOs in Alzheimer's Disease

Presence and Distribution

Tertiary lymphoid organs have been identified in AD brains:

• Subventricular zone: Dense lymphoid aggregates near lateral ventricles
• Hippocampal formation: Perivascular lymphoid structures
• Cerebral [cortex](/brain-regions/cortex): Scattered perivascular infiltrates
• Meningeal vessels: Subarachnoid lymphoid collections[@meningeal2021]

Pathogenic Role

In Alzheimer's disease, TLOs may contribute to:

Local [Aβ](/proteins/amyloid-beta) antibody production: Anti-Aβ antibodies can form immune complexes

Chronic neuroinflammation: Sustained pro-inflammatory cytokine environment

Neuronal damage: Cytotoxic CD8+ T cell-mediated killing

Disease progression: Correlation with cognitive decline severity[@cells2022]

Therapeutic Implications

Targeting TLOs in AD:

| Strategy | Approach | Status |
|----------|----------|--------|
| B cell depletion | Anti-CD20 antibodies | Under investigation |
| Cytokine blockade | Anti-LTβR, anti-IL-17 | Preclinical |
| Chemokine inhibition | CXCR5 antagonists | Research phase |
| Complement modulation | C1q inhibitors | Experimental |

TLOs in Parkinson's Disease

Identification in PD Tissues

TLOs have been detected in:

• Substantia nigra: Perivascular lymphoid aggregates
• Striatum: Follicular structures near blood vessels
• Brainstem nuclei: Scattered infiltrates
• Meninges: Subpial lymphoid collections[@tertiary2020]

Relationship to α-Synuclein Pathology

TLOs in PD may interact with [α-synuclein](/proteins/alpha-synuclein):

• Local antibody production against α-synuclein aggregates
• Immune complex deposition contributing to neurodegeneration
• Chronic microglial activation via Fc receptor signaling
• Potential for antigen-driven T cell responses

Neuroinflammation Amplification

TLOs may amplify neuroinflammation through:

Sustained cytokine production: Localized IL-1β, TNF-α, IL-6

Autoantibody generation: Anti-neuronal antibodies

Cellular infiltration: Continuous immune cell recruitment

Antigen presentation: Ongoing activation of T cells

TLOs in Multiple Sclerosis

Ectopic Lymphoid Follicles

In MS, TLOs are particularly prominent:

• Meningeal aggregates: Subpial lymphoid follicles (SFAs)
• Perivascular cuffs: Perivascular lymphoid collections
• Demyelinating lesions: Intralesional organized infiltrates[@meningeal2019]

Clinical Significance

Meningeal TLOs in MS correlate with:

• More severe disease course
• Younger age at onset
• Earlier disability progression
• Reduced treatment responsiveness
• Grey matter pathology

Therapeutic Targeting

MS treatments affecting TLOs:

• Natalizumab: Reduces immune cell trafficking
• Fingolimod: Modulates lymphocyte egress
• Ocrelizumab: Depletes B cells
• Alemtuzumab: Targets T and B cells

TLOs in Amyotrophic Lateral Sclerosis

Presence in ALS Tissues

Tertiary lymphoid organs have been observed in:

• Motor cortex: Perivascular lymphoid aggregates
• Spinal cord: Meningeal and parenchymal infiltrates
• Brainstem: Bulbar region lymphoid structures[@lymphoid2021]

Contribution to Neurodegeneration

In ALS, TLOs may:

Produce autoantibodies against motor [neurons](/entities/neurons)

Generate cytotoxic T cell responses

Sustain neuroinflammatory environment

Contribute to disease progression

TDP-43 Pathology Interaction

TLOs may interact with [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology:

• Local immune responses to TDP-43 aggregates
• Potential for antigen-driven degeneration
• Autoantibody production against misfolded proteins

Diagnostic and Therapeutic Implications

Biomarker Potential

TLOs as disease markers:

• Imaging targets: PET ligands for lymphoid tissue
• CSF markers: Cytokines indicating lymphoid neogenesis
• Histological markers: CD20, CD21, CD23 staining patterns

Therapeutic Strategies

Targeting TLOs in neurodegeneration:

Challenges

Key challenges in targeting TLOs:

Complexity: Multiple cell types and cytokines involved

Beneficial functions: Some TLO activity may be protective

[BBB](/entities/blood-brain-barrier) penetration: Drug delivery to CNS lymphoid structures

Patient selection: Identifying patients with prominent TLOs

Research Directions

Emerging Areas

Current research focus areas:

• Single-cell sequencing: Defining TLO cellular heterogeneity
• Spatial transcriptomics: Mapping lymphoid neogenesis in situ
• Live imaging: Visualizing TLO formation dynamics
• Organoid models: In vitro TLO recapitulation[@modeling2023]

Unanswered Questions

Key questions remaining:

What triggers TLO formation in neurodegeneration?

Are TLOs causative or consequential?

Can TLOs be reversed?

What is the balance of protective vs. pathogenic functions?

Which patient subgroups have prominent TLOs?

Cross-Linking

• [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation-pathway)
• [Microglial Activation in Alzheimer's Disease](/cell-types/microglia-alzheimers)
• [B Cell Involvement in Neurodegeneration](/cell-types/b-cells-neurodegeneration)
• [Autoimmunity in Parkinson's Disease](/diseases/parkinsons-disease)
• [Multiple Sclerosis Pathogenesis](/diseases/multiple-sclerosis)
• [Amyotrophic Lateral Sclerosis Mechanisms](/diseases/amyotrophic-lateral-sclerosis)
• [CXCL13 Signaling in Neurodegeneration](/mechanisms/cxcl13-signaling-neurodegeneration)
• [Lymphotoxin Signaling Pathway](/mechanisms/lymphotoxin-signaling-neurodegeneration)

See Also

• [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation-pathway)
• [Autoimmunity in Parkinson's Disease](/diseases/parkinsons-disease)
• [Multiple Sclerosis Pathogenesis](/diseases/multiple-sclerosis)
• [Amyotrophic Lateral Sclerosis Mechanisms](/diseases/amyotrophic-lateral-sclerosis)
• [CXCL13 Signaling in Neurodegeneration](/mechanisms/cxcl13-signaling-neurodegeneration)
• [Lymphotoxin Signaling Pathway](/mechanisms/lymphotoxin-signaling-neurodegeneration)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

• [A et al. 2025: Dural ectopic lymphatic structures accumulate during aging and exhibit](https://pubmed.ncbi.nlm.nih.gov/40794835/)

References

[Unknown, Tertiary lymphoid organs in autoimmune disease (Nat Rev Immunol, 2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29614433/)

[Unknown, Structure and function of tertiary lymphoid organs (Trends Immunol, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31279679/)

[Unknown, Cytokine requirements for lymphoid neogenesis (J Exp Med, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32615754/)

[Unknown, Meningeal lymphoid structures in Alzheimer's disease (Acta Neuropathol, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33959781/)

[Unknown, B cells and autoantibodies in Alzheimer's disease (Nat Rev Neurosci, 2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35411052/)

[Unknown, Tertiary lymphoid organs in Parkinson's disease brain (Acta Neuropathol, 2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32857263/)

[Unknown, Meningeal ectopic lymphoid follicles in multiple sclerosis (Brain, 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30951223/)

[Unknown, Lymphoid aggregates in amyotrophic lateral sclerosis (Acta Neuropathol Commun, 2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34059056/)

[Unknown, Modeling tertiary lymphoid organs in vitro (Cell Stem Cell, 2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36930978/)